Neurocrine Biosciences (NASDAQ:NBIX) said on Wednesday its experimental oral drug (NBI-1117568) to treat adults with schizophrenia met the primary goal in a mid-stage study. The NBI-'568-SCZ2028 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈